Adagene, Inc. (ADAG)
NASDAQ:ADAG
Want to see ADAG full AI Analyst Report?
ADAG Stock Chart & Stats
$3.97
-$0.15(-7.28%)
At close: 4:00 PM EST
$3.97
-$0.15(-7.28%)
Day’s Range― - ―
52-Week Range$1.30 - $4.75
Previous CloseN/A
Volume1.51K
Average Volume (3M)164.00K
Market Cap
$188.12M
Enterprise Value$81.20M
Total Cash (Recent Filing)$74.52M
Total Debt (Recent Filing)$6.26M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Sep 02, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding66,072,590
10 Day Avg. Volume192,485
30 Day Avg. Volume164,003
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.02
Price to Sales (P/S)9.30
P/FCF Ratio-4.55
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue10.56
Enterprise Value/Gross Profit11.42
Enterprise Value/Ebitda-3.88
Forecast
1Y Price Target
$8.33Price Target Upside109.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy & SafetyRobust, reproducible response rates and manageable high-grade toxicity in Phase 1b/2 triplet data support muzastotug’s differentiated clinical profile. Durable efficacy with limited severe AEs strengthens its role as a backbone combo agent, improving probability of progressing to registrational trials and sustained clinical adoption.
Strategic PartnershipsBroad, high-profile collaborations provide access to complementary assets, development expertise and shared trial networks. Partnering reduces single-party cost burden, accelerates combination studies, and de-risks clinical pathway execution—improving chances of late-stage success and commercial viability over several years.
Improved Liquidity & RunwayMeaningful year-end cash and an extended runway into early 2028 give management time to complete key dose-optimization and randomized Phase 2 work without immediate financing. This funding window supports enrollment, regulatory interactions, and partner-enabled studies, lowering short-term execution risk.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow forces recurring external financing to fund R&D and operations. Over 2–6 months this raises the probability of dilutive raises or restrictive covenants, which can constrain strategic flexibility and increase shareholder dilution risk if milestones slip.
Revenue & Gross Profit VolatilityLarge revenue swings and prior negative gross profit indicate unpredictable partner payments and inconsistent margin generation. This undermines the stability of contract revenue as a reliable funding source, complicates multi-year planning, and raises execution risk for scaling operations and late-stage programs.
Persistent Losses & Negative ROEContinued operating and net losses mean the company is not generating returns on invested capital. Even with lower leverage, sustained negative ROE points to value dilution risk and dependence on successful trial outcomes to justify further investment, making long-term capital efficiency uncertain.
Adagene News
ADAG FAQ
What was Adagene, Inc.’s price range in the past 12 months?
Adagene, Inc. lowest stock price was $1.30 and its highest was $4.75 in the past 12 months.
What is Adagene, Inc.’s market cap?
Adagene, Inc.’s market cap is $188.12M.
When is Adagene, Inc.’s upcoming earnings report date?
Adagene, Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 93 days.
How were Adagene, Inc.’s earnings last quarter?
Adagene, Inc. released its earnings results on Apr 01, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.02.
Is Adagene, Inc. overvalued?
According to Wall Street analysts Adagene, Inc.’s price is currently Undervalued.
Does Adagene, Inc. pay dividends?
Adagene, Inc. does not currently pay dividends.
What is Adagene, Inc.’s EPS estimate?
Adagene, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Adagene, Inc. have?
Adagene, Inc. has 66,072,590 shares outstanding.
What happened to Adagene, Inc.’s price movement after its last earnings report?
Adagene, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -13.449%.
Which hedge fund is a major shareholder of Adagene, Inc.?
Currently, no hedge funds are holding shares in ADAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adagene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (109.91% Upside)
$8.33 (109.91% Upside)
Blogger Sentiment
Bullish
ADAG Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 11.7%
Last 30 Days ▼ 10.8%
Last 30 Days ▼ 10.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.06%
12-Months-Change
Fundamentals
Return on Equity
-48.20%
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
Adagene, Inc.
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
ADAG Stock 12 Month Forecast
Average Price Target
$8.33
▲(109.91% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
3.72% Other Institutional Investors
96.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---